Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.40 |
| ▸ | GAA | P10253 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 7/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071901 | 0.81 | RECQL (0.67) | RECQLL3MBTL1KDM4EGAAMAPT | |
| SCHEMBL2908653 | 0.77 | POLB (0.48) | RECQLL3MBTL1KDM4EGAAMAPT | |
| SCHEMBL4067248 | 0.76 | RECQL (0.59) | RECQLL3MBTL1KDM4EGAAMAPT | |
| SCHEMBL9818229 | 0.74 | SMN1; SMN2 (0.47) | RECQLL3MBTL1KDM4EGAAMAPT | |
| SCHEMBL2911052 | 0.74 | L3MBTL1 (0.48) | RECQLL3MBTL1KDM4EGAAMAPT | |
| SCHEMBL8441200 | 0.72 | KDM4E (0.42) | RECQLL3MBTL1KDM4EGAAMAPT | |
| SCHEMBL2908493 | 0.72 | ALDH1A1 (0.42) | L3MBTL1KDM4EGAAMAPTAPOBEC3G | |
| SCHEMBL17164107 | 0.71 | RECQL (0.70) | RECQLL3MBTL1KDM4EGAAMEN1 | |
| SCHEMBL31587296 | 0.71 | TSHR (0.40) | L3MBTL1KDM4EGAAMAPTMEN1 | |
| SCHEMBL318407 | 0.70 | KDM4E (0.60) | RECQLL3MBTL1KDM4EGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071776-B2 | Thienopyridines as allosteric potentiators of the M4 muscarinic receptor | ELI LILLY AND COMPANY (US) | 2011-12-06 | — | — | US | disclosed |
| EP-1807434-B1 | THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR | LILLY CO ELI (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090105244-A1 | THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR | ELI LILLY AND COMPANY (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1807434-A1 | THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006047124-A1 | THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR | ELI LILLY AND COMPANY (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105244-A1 | THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR | CHRM2, CHRM4, CHRM1 | RECQL 2814/4885L3MBTL1 3031/4885KDM4E 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.